Acumen Pharmaceuticals, Inc.
ABOSHealthcare|Biotechnology|US
$0.22
+0.01 (+4.54%)
DCF Value
$0.38
Tangible Book / Share
$0.48
Cash / Share
$1.09
About
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Stock Price
-88.2%(1Y)
1M
-89.4%
3M
-90.8%
6M
-91.3%
YTD
-89.4%
1Y
-88.2%
3Y
-89.0%
5Y
-98.5%
Pipeline Summary
3 total trials2
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Active: 1Completed: 2
Active Trials (1)
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
NCT06335173Alzheimer Disease
Phase 2Active
Enrollment: 542 participants
Key Facts
Market Cap$16.2M
Employees60 (-2% YoY)
CEODaniel J. O'Connell
IPO DateJul 1, 2021
Beta0.33
52-Week Range$0.191 – $3.6
Avg Volume1,841,620
ExchangeNASDAQ
Websiteacumenpharm.com
Ownership
Float85.4%
Shares Outstanding72.3M
Recent Insider Trades
Porter DerrellOPTION EX.
Jun 15, 20266,460 shares @ $1.07
Porter DerrellOPTION EX.
Jun 17, 202613,040 shares @ $1.07
Porter DerrellSELL
Jun 15, 20266,460 shares @ $2.35
Porter DerrellSELL
Jun 17, 202613,040 shares @ $2.33
Porter DerrellSELL
Jun 16, 202612,800 shares @ $2.33
Peers
Recent News
Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
Nov 4, 2026 · fool.com
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer's Disease; Trial Did Not Meet Primary Endpoint
Oct 30, 2026 · globenewswire.com
Acumen Pharmaceuticals: A Speculative Buy Ahead Of November's Alzheimer's Readout
Oct 28, 2026 · seekingalpha.com
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript
Oct 26, 2026 · seekingalpha.com
Acumen Pharmaceuticals Q3 Earnings Call Highlights
Oct 26, 2026 · marketbeat.com
Data last updated: Nov 9, 2026, 03:51 AM